ABSTRACT
Liver transplantation is a life-saving as well as a life-changing procedure for patients with advanced chronic liver disease, hepatocellular carcinoma, and acute liver failure (Kallwitz 2012).
Survival rates after liver transplantation have reached 85% at 5 years post transplant and as high as 56% at 20 years post transplant, in the two last decades. However, the improved survival of patients following liver transplantation (LTx) has been accompanied by an increased prevalence and incidence of chronic diseases over that of the general population (Adam and Hoti 2009, Duffy et al. 2010). Metabolic disorders are signicantly higher in this subgroup of individuals, affecting more than half of the patients (Bianchi et al. 2008, Hanoueh et al. 2008, Kallwitz 2012, Laryea et al. 2007).
